Tegaserod: Long-term treatment for irritable bowel syndrome patients with constipation in primary care

Digestion

Volumn 71, Issue 4, 2005, Pages 238-244

  Layer, Peter ^a,e   Keller, Jutta ^a   Mueller Lissner, Stefan ^b   Rüegg, Peter ^c   Loeffler, Helena ^d  

^a ISRAELITISCHES KRANKENHAUS   (Germany)

^b Park Klinik Weissensee   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS PHARMA GMBH   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Abdominal pain discomfort; Bloating; Constipation; Irritable bowel syndrome (IBS); Primary care; Prokinetic; Tegaserod

Indexed keywords

CISAPRIDE; TEGASEROD;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOATING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES ANALYSIS; FEMALE; HEADACHE; HUMAN; IRRITABLE COLON; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

CONSTIPATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 23844527230     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087049     Document Type: Article

References (31)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Mueller-Lissner SA: Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl):43-47.
2. Camilleri M: Management of the irritable bowel syndrome. Gastroenterology 2001;120:652-668.
3. Mueller-Lissner SA, Bollani S, Brummer RJ, Coremans G, Dapoigny M, Marshall JK, Muris JW, Oberndorff-Klein Wolthuis A, Pace F, Rodrigo L, Stockbrugger R, Vatn MH: Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 2001; 64:200-204.
4. Hungin APS, Whorwell P, Tack J, Mearin F: The prevalence, patterns and impact of irritable bowel syndrome: An international study of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643-650.
5. Icks A, Haastert B, Enck P, Rathmann W, Giani G: Prevalence of functional bowel disorders and related health care seeking: A population-based study. Z Gastroenterol 2002;40: 177-183.
6. Schuster MM: Defining and diagnosing irritable bowel syndrome. Am J Manag Care 2001; 7(suppl):S246-S251.
7. Icks A, Haastert B, Enck P, Rathmann W, Giani G: Health-related quality of life in subjects with functional bowel disorders in Germany. Z Gastroenterol 2002;40:863-867.
8. Mueller-Lissner SA, Pirk O: Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol 2002;14:1325-1329.
9. Hungin P, Chang L, Barghout V, Kahler K: The impact of IBS on absenteeism and work productivity: United States and eight European countries. Am J Gastroenterol 2003;98:S227.
10. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, Richter JE, Koch GG: US householder survey of functional gastrointestinal disorders - Prevalence, sociodemography and health impact. Dig Dis Sci 1993;38:1569-1580.
11. Somers SC, Lembo A: Irritable bowel syndrome: Evaluation and treatment. Gastroenterol Clin North Am 2003;32:507-529.
12. Mueller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Rueegg P: Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15: 1655-1666.
13. Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, Rueegg P, Lefkowitz M: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16: 1877-1888.
14. Cremonini F, Delgado-Aros S, Camilleri M: Efficacy of alosetron in irritable bowel syndrome: A meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15:79-86.
15. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, Gwee KA, Bak YT, Jones J, Wagner A: An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-676.
16. Nyhlin H, Bang C, Elsborg L, Silvennoinen J, Holme I, Rueegg P, Jones J, Wagner A: A double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004; 39:119-126.
17. Grider JR, Foxx-Orenstein AE, Jin JG: 5-Hydroxytryptamine 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998;115:370-380.
18. Jin JG, Foxx-Orenstein AE, Grider JR: Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 1999;288: 93-97.
19. Stoner MC, Arcuni JC, John JL, Kellum M: A selective 5-HT4 receptor agonist induces cAMP-mediated Cl efflux from rat colonocytes. Gastroenterology 1999;116:G287.
20. Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D: Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003 15;17:577-585.
21. Nguyen A, Camilleri M, Kost LJ, Metzger A, Sarr MG, Hanson RB, Fett SL, Zinsmeister AR: SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997;280:1270-1276.
22. Appel S, Kumle A, Meier R: Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997;62:546-555.
23. Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Osborne S, Luchinger S, Bertold R, Maecke H, Beglinger C: Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15:1745-1751.
24. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-468.
25. Lefkowitz M, Shi Y, Schmitt C, Krumholz S, Tanghe J: The 5-HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS). Am J Gastroenterol 1999;94:266.
26. O'Donnell LJD, Virjee J, Heaton KW: Detection of pseudodiarrhea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300:439-440.
27. Camilleri M: Review article: Tegaserod. Aliment Pharmacol Ther 2001;15:277-289.
28. Mueller-Lissner S, Holtmann G, Rueegg P, Weidinger G, Loeffler H: Tegaserod is effective in the initial and re-treatment of irritable bowel syndrome with constipation (IBS-C). Aliment Pharmacol Ther 2005;21:11-20.
29. Spiller RC: Problems and challenges in the design of IBS clinical trials: Experience from published trials. Am J Med 1999;107:91s-97s.
30. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramon BE, McKinzie S, Urrutia R: Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123:425-432.
31. Appel S, Kumle A, Hubert M, Duvauchelle T: First pharmacokinetic- pharmacodynamic study in humans with a selective 5-hydroxytryptamine 4 receptor agonist. J Clin Pharmacol 1997;37:229-237.